Literature DB >> 301020

Experience with interposition mesocaval shunt for management of variceal bleeding.

H S Filtzer, R Rossi, F G Wolfort.   

Abstract

We present an experience with 20 patients undergoing interposition mesocaval shunts for decompression of esophageal varices. There were 14 men and six women, ranging in age from 32 to 80 years. Two patients were classified as good risks, nine as moderate risks, and nine as poor risks. There were ten elective operations, seven urgent operations, and three emergency procedures. An operative mortality of 10% was noted in the entire group, with one late death due to shunt occlusion. All deaths occured in the emergency group. A shunt patency of 88% and minimal problems with postoperative hepatic encephalopathy were noted. The interposition mesocaval shunt is judged to be a safe, technically easy procedure that is currently a satisfactory solution to the problem of hemorrhage from esophageal varices.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 301020     DOI: 10.1001/archsurg.1977.01370050053008

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  4 in total

1.  Surgery for variceal bleeding in cirrhosis: a review of our experience and present concepts.

Authors:  N Ramakrishna; J G Martin
Journal:  J Natl Med Assoc       Date:  1979-05       Impact factor: 1.798

2.  Results of interposition "H" grafts for portal hypertension.

Authors:  B W Thompson; R E Casali; R C Read; G S Campbell
Journal:  Ann Surg       Date:  1978-05       Impact factor: 12.969

3.  Esophageal transection with paraesophagogastric devascularizations (the Sugiura procedure) in the treatment of esophageal varices.

Authors:  M Sugiura; S Futagawa
Journal:  World J Surg       Date:  1984-10       Impact factor: 3.352

4.  Dacron interposition shunts for portal hypertension. An analysis of morbidity correlates.

Authors:  R B Smith; W D Warren; A A Salam; W J Millikan; J D Ansley; J T Galambos; M Kutner; R P Bain
Journal:  Ann Surg       Date:  1980-07       Impact factor: 12.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.